Class
Long-acting GHRH Analogue with Drug Affinity Complex
Molecular Weight
3,647.3 Da
Half-life
6–8 days (albumin-bound)
Purity
≥98% (HPLC)
Form
Lyophilized powder
Storage
Lyophilized: −20°C; Reconstituted: 4°C
Reconstitution
Bacteriostatic water
Mechanism of action
CJC-1295 with DAC is a synthetic GHRH analogue modified with a maleimidoproprionic acid Drug Affinity Complex that enables covalent binding to endogenous serum albumin, dramatically extending plasma half-life from the native 7-minute half-life to approximately 6–8 days. This creates sustained GHRH receptor stimulation on pituitary somatotrophs, resulting in continuous GH release and persistent elevation of downstream IGF-1 over an extended period.
⚠️ For Research Use Only — described exclusively for in vitro and laboratory research by qualified researchers. Not for human or veterinary use. Informational only; does not constitute medical advice or imply efficacy in humans.
Research highlights
6–8 days
Plasma half-life (vs 7 min for native GHRH)
↑↑ IGF-1
Persistent IGF-1 elevation — weeks per injection
0
Cortisol/prolactin elevation (unlike GHRP-6)
Synergy
Combines with Ipamorelin for amplified GH pulses
Research notes
- Sustained GH: DAC technology creates "GH bleed" — continuous low-level GH release between pulses; distinct profile vs shorter analogues.
- IGF-1: Studies show IGF-1 remaining elevated for 2–3 weeks following a single injection in animal models.
- Lean mass: Animal studies demonstrate increased lean mass and reduced adipose tissue over extended protocols.
- Clean profile: No significant elevation of cortisol, prolactin, or ACTH observed, unlike older GHRPs.
- Combination research: CJC-1295 DAC + Ipamorelin combination studied for synergistic GH pulse amplification.
